AstraZeneca (AZN.US) and Daiichi Sankyo (DSNKY.US) TROP2 ADC receives approval for new indication in China
智通财经2026/10/08 08:46According to information from Zhihu Finance APP, AstraZeneca (AZN.US) and Daiichi Sankyo (DSNKY.US) have announced that Datroway® (generic name: datopotamab deruxtecan for injection) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not suitable for PD-1/PD-L1 inhibitor therapies. Datopotamab deruxtecan is an antibody-drug conjugate (ADC) targeting TROP2, developed with proprietary technology by Daiichi Sankyo, and jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI transformation dividends strengthen profit growth logic! SAP (SAP.US) upgraded to "Overweight" by JPMorgan, target price raised to 275 euros
JPMorgan has upgraded its rating on SAP from "Neutral" to "Overweight" in its latest report, raising the target price from 175 euros in December 2027 to 275 euros in December 2028, implying an upside potential of approximately 30%.
Nymex US crude oil futures main contract at $89.99 per barrel, down 0.92% intraday
Crypto prices
More
